Navigation Links
Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
Date:7/8/2009

CAMBRIDGE, England, July 8 /PRNewswire/ -- Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).

The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed. The pharmacokinetics of FX125L was linear over the wide dose range studied and consistent with once-daily oral dosing for patients.

"We are extremely pleased with the outcome of this initial clinical study with FX125L," said Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics. "The results in humans are consistent with the preclinical data, suggesting that FX125L has a very wide safety margin, and confirmed the excellent drug-like profile of FX125L."

About Funxional Therapeutics Ltd.

Funxional Therapeutics is a privately held, clinical stage pharmaceutical company based in Cambridge (UK) which focuses on novel anti-inflammatory therapies. FXT is managed by a very experienced team and is financed by Index Ventures and Novo A/S, while its shareholders also include Ipsen and Cambridge University. FXT has research and office facilities in Cambridge.

For more information about FXT, please visit our web site (http://www.funxionaltherapeutics.com) or contact us by e-mail (info@funxionaltherapeutics.com).

About BSCIs

BSCIs are anti-inflammatory compounds with an entirely novel mechanism of action that involves the selective int
'/>"/>

SOURCE Funxional Therapeutics Limited
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
2. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
3. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
4. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
5. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
6. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
7. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
8. Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
9. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
10. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
11. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... The New York investment bank ...SX:NEU) has agreed an AU$6.7 mil convertible note ...or. The private placement was arranged by KTA Capi...sor. , New York (PRWEB) N...tment bank KTA Capital, LLC ("KTA Capital&quo...
(Date:11/24/2009)... , REYKJAVIK, Iceland, Novemb...nc. (Nasdaq: DCGN ) today announced that it has re...ading in the company,s common stock will be,suspen... be filed with the,Securities and Exchange Commiss...listing on Nasdaq, unless the company files an app...
(Date:11/24/2009)... , REYKJAVIK, Iceland, Novemb...nc. (Nasdaq: DCGN ) today announced the approval o...uptcy Court for the District of Delaware,(the "Ban...y petition for,relief under Chapter 11 of the Unit...t. , The orders issued by the Bankruptcy ...
(Date:11/24/2009)... , SHANGHAI, Nov. 24 /PRNewswire-Asia...Food & Drug Administration (SFDA) has approved...r its oral insulin project,(Nodlin), an innovative...pproval allows Biolaxy to initiate its first phase...er characteristic of high blood glucose and poor,m...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2
...Calif., April 23 STAAR Surgical,Company (Nasdaq: ...keter of,minimally invasive ophthalmic products, t...rst of its nine-part webinar series on the Company... first session which aired,Tuesday, April 22, 2008...Me," is part of a new marketing initiative designe...
...weden and CAMBRIDGE, England, April 23 Two,leadin...covery (FBDD) today,announced a new commercial all...e, UK, and Beactica AB, based in Uppsala, Sweden, ...d lead discovery and optimization,platform., The ...-directed FBDD,libraries to state-of-the-art fragm...
...PS Increased 22 Percent, CAMBRIDGE, Mass., April ...orted results for the first quarter of,2008, which...ating,leverage, a significant increase in non-GAAP... First-Quarter Highlights -- Total revenue for t... $883.2 million in same period a year ago. This ...
Other Biology Technology:More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch 2More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch 3New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden) 2Genzyme Reports Strong First-Quarter Growth 2Genzyme Reports Strong First-Quarter Growth 3Genzyme Reports Strong First-Quarter Growth 4Genzyme Reports Strong First-Quarter Growth 5Genzyme Reports Strong First-Quarter Growth 6Genzyme Reports Strong First-Quarter Growth 7Genzyme Reports Strong First-Quarter Growth 8Genzyme Reports Strong First-Quarter Growth 9Genzyme Reports Strong First-Quarter Growth 10Genzyme Reports Strong First-Quarter Growth 11Genzyme Reports Strong First-Quarter Growth 12Genzyme Reports Strong First-Quarter Growth 13Genzyme Reports Strong First-Quarter Growth 14Genzyme Reports Strong First-Quarter Growth 15Genzyme Reports Strong First-Quarter Growth 16Genzyme Reports Strong First-Quarter Growth 17Genzyme Reports Strong First-Quarter Growth 18Genzyme Reports Strong First-Quarter Growth 19
(Date:11/24/2009)...te (LRI) today named 12 new grant recipients for 2...innovative work across a broad spectrum of lupus r...ovelty, and potential to drive scientific discover...ex disease of systemic lupus. , The 2009 grants ...cross the nation and include interdisciplinary and...
(Date:11/24/2009)...and flabby arteries from collapsing have been true...re no longer needed -- once the arteries are stren...ors had no choice but to leave them in place. , ...partment of Biomedical Engineering has developed a...ugs where they,re needed, then dissolves. , "Our...
(Date:11/24/2009)...November 24, 2009) -- The Wildlife Conservation So...t the last remaining population of Siberian tigers...ng tide of poaching and habitat loss. , ...fficials of what needs to be done to protect remai... The report was released by the Siberia...
Breaking Biology News(10 mins):Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3A coating for life 2Report shows dramatic decline in Siberian tigers 2Supplement Might Help Compulsive Hair Pullers 50970 1Supplement Might Help Compulsive Hair Pullers 50970 2King Provides Additional Information on the REMOXY 28R 29 NDA Resubmission Plan 50967 1King Provides Additional Information on the REMOXY 28R 29 NDA Resubmission Plan 50967 2World Financial Crisis and AIDS Backlash Threaten Lives 50964 1World Financial Crisis and AIDS Backlash Threaten Lives 50964 2World Financial Crisis and AIDS Backlash Threaten Lives 50964 3
...ia (Oct. 17, 2007) The Nature Conservancy and Con...nments of the United States and Costa Rica in one ... The agreement will ensure the protection of Cost...s, with the United States forgiving $26 million of...unt on tropical forest conservation programs over ...
...s have been identified in 47-million year old lake...nus Anacardium was once distributed in Europe, rem... and South America. It was previously proposed tha...ra, diverged from their common ancestor when the l...owever, groundbreaking new data in the October iss...
...e University of Rochester believe they have just c...X chromosome is a strikingly powerful force in the...r years whether the X chromosomethe female chromos...cess of speciation. In a new study in the journal ...gy at the University of Rochester, has confirmed t...
Other Biology News:Costa Rica, US announce historic debt-for-nature swap 2Costa Rica, US announce historic debt-for-nature swap 3Fossilized cashew nuts reveal Europe was important route between Africa and South America 2X-effect: female chromosome confirmed a prime driver of speciation 2
...X Fernbach-style culture flask is designed for cul... volume ratio. It can also be used in serum produc...o achieve maximal oxygen transfer to culture mediu...accepts cotton plugs or No. 13 rubber stoppers. Th...
...emplate is designed to allow neomycin/kanamycin se...FRT-PGK-gb2-neo-FRT template encodes the neomycin/...otic promoter (gb2) for expression of kanamycin re...GK) for expression of neomycin resistance in mamma...
Corning disposable NMR tube caps, 5mm from Sigma-Aldrich
...r, 7 inch long PYREX NMR tubes are made from quali...d joints, valves, and vacuum racks. They are desig...to 500MHz. They have an O.D. of 4.97 + 0.000-0.013...tubes can be used with the PYREX Microcell system ...
Biology Products: